home
•
contacts
•
sitemap
•
search
About
Company Overview
Company History
Leadership Team
Board of Directors
Company Values
Careers
Products
Development Pipeline
Partnered Programmes
Marketed Products
Product Supplies
Business Development
Partnering
Business Development Contacts
Investors
Share Price Data
Press Releases
Regulatory Announcements
Financial Reports & Accounts
Financial Results
Presentations
BTG Share Dealing Facility
Email Alerts
Financial Calendar
Corporate Governance
Analyst Research
Investor Contacts
Responsibility
Our Approach to Responsibility
Employment Practices, Human Rights and Ethics
Research and Development Practice
Suppliers, Products and Customers
Community
Environment
News
Press Releases
Events
Email Alerts
Media Contact
Products
Development Pipeline
Voraxaze™
Varisolve
®
OncoGel™
Angiotensin Therapeutic Vaccine
BGC20-0134 (Pleneva™)
BGC20-1531
Partnered Programmes
Campath
®
CB7630 (abiraterone)
Otelixizumab (TRX4)
AZD9773 (CytoFab™)
ABIO-0801
Juvidex™
Modafinil Combination
Acadra™
Nexvax2
ONX 0801
β-Amyloid Inhibitors
Marketed Products
Product Supplies
Products
>
Partnered Programmes
Partnered Programmes
In addition to its growing pipeline of
development programmes
, BTG has assets in development with its partners.
Print
version
Preclinical
Phase I
Phase II
Phase III
Campath
®
(Genzyme Corporation)
Multiple Sclerosis
CB7630 (abiraterone)
(Cougar Biotechnology/J & J)
Prostate cancer
Advanced breast cancer
Otelixizumab (TRX4)
(Tolerx/GSK)
Type 1 diabetes
Rheumatoid arthritis
AZD9773 (CytoFab™)
(AstraZeneca)
Severe sepsis
ABIO-0801
(Abiogen Pharma)
Anxiety
Juvidex™
(Renovo)
Accelerated healing & scar improvement
Modafinil Combination
(Victory Pharma)
Opiate-induced sleepiness
Acadra™
(Advancell S.A.)
B-cell Chronic Lymphocytic Leukaemia
Nexvax2
(Nexpep)
Coeliac disease
ONX 0801
(Onyx Pharmaceuticals)
Solid Tumours
β-Amyloid Inhibitors
(Senexis)
Alzheimer's disease
© BTG International Ltd 2010 •
Legal Notice
•
Accessibility